ArticleAIMS microbiology2017
Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes.
Article in AIMS microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Limitations and safety aspects related to the use of bacteriophages in food production.FEMS microbiology reviews · 2026Article
- Review
- How Simple Maths Can Inform Our Basic Understanding of Phage Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Automating Predictive Phage Therapy Pharmacology.Antibiotics (Basel, Switzerland) · 2023Review
- Bacteriophage Adsorption: Likelihood of Virion Encounter with Bacteria and Other Factors Affecting Rates.Antibiotics (Basel, Switzerland) · 2023Review
- A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics-Leveraging Principles of Systems Biology.Pathogens (Basel, Switzerland) · 2023Review
- Further Considerations on How to Improve Phage Therapy Experimentation, Practice, and Reporting: Pharmacodynamics Perspectives.PHAGE (New Rochelle, N.Y.) · 2022Review
- Pathways to Phage Therapy Enlightenment, or Why I Have Become a Scientific Curmudgeon.PHAGE (New Rochelle, N.Y.) · 2022Article
- Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective.Frontiers in cellular and infection microbiology · 2022Review
- Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?Pharmaceuticals (Basel, Switzerland) · 2021Article
- Improving Phage-Biofilm In Vitro Experimentation.Viruses · 2021Article
- Safety and Efficacy of a Phage, kpssk3, in anFrontiers in microbiology · 2021Article
- Evaluation of Phage Delivery Systems on Induced MotilePHAGE (New Rochelle, N.Y.) · 2020Article
- Bacteriophage treatment of carbapenemase-producingAIMS microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages can be used as antibacterial agents as a form of biological control, e.g., such as phage therapy. With active treatment, phages must "actively" produce new virions,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.